Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P05231 (
interleukin-6
)
23,907
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Objectives.
In this study, we assessed the extra-articular symptoms in constellation with selected serum cytokines and disease activity in spondyloarthritis (SpA).
Patients and Methods.
We studied 287 SpA patients: 131 had AS, 110 had PsA, and 46 had SAPHO. We assessed extra-articular symptoms in all cases. In 191 SpA patients, we measured serum
interleukin-6
(
IL-6
), interleukin-18 (IL-18), interleukin-23 (IL-23), endothelin-1 (ET-1), vascular endothelial growth factor (VEGF), and epidermal growth factor (EGF).
Results.
Patients with acute anterior uveitis (AAU) had higher VAS (
P
= 0.0008), BADSDAI (
P
= 0.0001), ASDAS-ESR (
P
= 0.04), CRP (
P
= 0.006),
IL-6
(
P
= 0.02), and IL-18 (
P
= 0.03) levels. Patients with inflammatory bowel disease (IBD) had higher VAS (
P
= 0.03), CRP (
P
= 0.0009), and
IL-6
(
P
= 0.0003) levels. Patients with skin psoriasis had lower VAS (
P
= 0.001) and BASDAI (
P
= 0.00007) levels. Patients with psoriatic
onycholysis
had lower VAS (
P
= 0.006), BASDAI (
P
= 0.00001), and CRP (
P
= 0.02) and higher IL-23 (
P
= 0.04) levels. Patients with PPP had lower BASDAI (
P
= 0.04) and higher ET-1 (
P
= 0.001) levels.
Conclusions.
SpA patients with increased serum IL-18 and decreased serum ET-1 had an increased risk of extra-articular symptoms. In SpA patients, increased disease activity was associated with an increased risk of AAU and IBD and a decreased risk of skin psoriasis, psoriatic
onycholysis
, and PPP.
...
PMID:Extra-Articular Symptoms in Constellation with Selected Serum Cytokines and Disease Activity in Spondyloarthritis. 2805 73